An interventional study of TDtect in Tardive Dyskinesia, sponsored by iRxReminder. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by iRxReminder · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.
Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 with no phase, and was the 26th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Neurocrine Biosciences · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18–75
Neurocrine Biosciences · Sites in United States
Ages 18+
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
Power Life Sciences Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 8
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 89 across the 27 interventional studies, 70 across the 3 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with iRxReminder as lead sponsor.
iRxReminder has 1 study filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
2 of the studies in Tardive Dyskinesia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365462Neurocrine BiosciencesEfficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | 2027-02 |
| NCT06997198University Hospitals Cleveland Medical CenterDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Tardive Dyskinesia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia. Participants will all be taking an antipsychotic medication and half will have a diagnosis of Tardive Dyskinesia and half will not. Participant responses to interview questions and elements of the Abnormal Involuntary Movement Scale will be collected on video. The videos will be rated by trained observers. Machine learning methods will be used to develop an algorithm to detect abnormal movements in individuals with a known Tardive Dyskinesia diagnosis. The trained rater results will be compared to the algorithm to determine the accuracy of the algorithm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the non-TD group:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: TDtect
Other: TDtect
Collecting video data on abnormal movement
AIMS Score
Abnormal Involuntary Scale Score
Time frame: Baseline
Started May 2023 (actual). Primary completion is estimated for Nov 2024, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.